Novo and Pfizer say MFN pricing agreements remain unchanged despite Democratic gains in Congress

On their third‑quarter earnings calls, the CEOs of Novo Nordisk and Pfizer said the Most Favored Nation drug‑pricing contracts they signed under the previous administration are still in effect and will not be altered by the recent shift in congressional control.

Both executives emphasized that their pricing arrangements are built on bipartisan support and that their companies will continue to work with whichever party holds power to ensure access to medicines at scale.

Analysts note that while Democrats may eventually revisit drug‑pricing policy, they are likely to prioritize other legislative matters in the near term, though investigations into pricing practices could still arise.